<DOC>
	<DOCNO>NCT02242344</DOCNO>
	<brief_summary>Study assess blood pressure lower effect two dos telmisartan four-week treatment period ; determine potentially effective dos pediatric patient future study ; ass safety tolerability two dos telmisartan . Pharmacokinetic objective include determination steady-state pharmacokinetics telmisartan child adolescent age 6 &lt; 18 year , determine age-related difference exist</brief_summary>
	<brief_title>Evaluation Safety , Efficacy Pharmacokinetics MICARDIS® ( Telmisartan ) Children Adolescents With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>1 . Male female child adolescent 6 &lt; 18 year age time inform consent/assent 2 . Ability provide write informed consent accordance Good Clinical Practice ( GCP ) local Institutional Review Boards ( IRBs ) , and/or patient assent , appropriate 3 . Ability stop current antihypertensive therapy without unacceptable risk patient ( Investigator 's discretion ) 4 . Weight ≥20 kg ≤120 kg 5 . Hypertensive patient : inclinic seat SBP ≥ 95th percentile base age , height , gender define The Fourth Report Diagnosis , Evaluation Treatment High Blood Pressure Children Adolescents 6 . Ability swallow whole tablet 1 . Hypertension accompany symptom sign central nervous system injury , include stroke , seizure , encephalopathy , within 6 month prior enrollment study 2 . Children whose inclinic seat BP measurement 20 mmHg SBP 10 mmHg DBP 95th percentile base The Fourth Report Diagnosis , Evaluation Treatment High Blood Pressure Children Adolescents 3 . Bilateral renal artery stenosis , unilateral renal artery stenosis solitary kidney , uncorrected coarctation aorta 4 . Congestive heart failure , valvular disease , clinically significant cardiac rhythm disturbance 5 . Bone marrow transplantation 6 . Solid organ transplantation 7 . Stroke 8 . Chronic Kidney Disease Glomerular Filtration Rate ( GFR ) &lt; 40 ml/min/1.73m2 Schwartz formula : Estimated GFR = ( k x Height [ cm ] / Serum Creatinine ( mg/dL ) . k = 0.55 female boys &lt; 13 year old ; k = 0.7 adolescent male ≥13 year old ) 9 . Clinically significant hepatic disease abnormal liver function test : 1 . Serum GlutamateOxaloacetateTransaminase ( Aspartate Aminotransferase ) ( SGOT ) , Serum GlutamatePyruvateTransaminase ( Alanine Aminotransferase ) ( SGPT ) , GammaGlutamylTransferase ( GGT ) 2x upper limit normal 2 . Total direct bilirubin 1.5x upper limit normal 10 . Clinically significant gastrointestinal disease may affect drug absorption excretion ( include gastroesophageal reflux , malabsorption , biliary disease , pancreatic disease ) 11 . Hyponatremia ( serum sodium ≤130 mEq/L ) , hyperkalemia ( Serum potassium ≥ 5.5 mEq/L ) , clinically significant electrolyte disorder 12 . Significant hypoalbuminemia ( serum albumin ≤2.5 g/dL ) 13 . Clinically significant neurological , psychiatric , pulmonary , hematological , condition , opinion Investigator , interfere safe successful completion study 14 . Hypersensitivity angiotensin II receptor antagonists 15 . Females childbearing potential : 1. pregnant/have positive urine pregnancy test ( UPT ) prior randomization ( Visit 2 ) , 2. nursing , lactating , 3. would confirm abstinence ( patient must abstinent throughout duration trial ) , 4. currently practice one acceptable method birth control . Acceptable method birth control limit : IntraUterine Device ( IUD ) , oral , implantable injectable contraceptive estrogen patch . 16 . Concomitant therapy follow agent : Any angiotensin II receptor antagonist within four ( 4 ) week prior randomization study Any medication could affect BP Angiotensin Converting Enzyme ( ACE ) inhibitor within four ( 4 ) week prior randomization study Intravenous pulse steroid therapy within one month , daily treatment oral corticosteroid ≥1 mg/kg/day ) Anticonvulsant medication Bile acid bind agent Any drug may interfere absorption study medication ( e.g.antacids ) Drugs may affect gastrointestinal motility ( e.g . metoclopramide ) Cytotoxic agent within 12 month prior enrollment study 17 . Other investigational drug treatment within 30 day prior enrollment 18 . Patients require two antihypertensive medication 19 . Hereditary fructose intolerance 20 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>